Stephen R Dugan

age ~48

from Lafayette, CA

Get Report

Also known as:

Stephen Robert Dugan
Steve Dugan
Stephen R Durgan
Steven Dugan

Connected to:

Stephen Dugan Phones & Addresses

Lafayette, CA
Estero, FL
26 Mizpah St, San Francisco, CA 94131 • 4158599488
Berkeley, CA
Grand Rapids, MI
26 Mizpah St, San Francisco, CA 94131

Us Patents

Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders With An Implantable Medical Device
view source
US Patent:

8435550, May 7, 2013
Filed:

Aug 13, 2008
Appl. No.:

12/191209
Inventors:

Jin Cheng - San Jose CA, US
Stephen Dugan - Berkeley CA, US
Gordon Stewart - San Francisco CA, US
Gina Zhang - Calabasas CA, US
Nancy Kirsten - Tucson AZ, US
Paul Consigny - San Jose CA, US
Christopher Feezor - San Jose CA, US
Gene Park - Santa Rosa CA, US
Wouter Roorda - Palo Alto CA, US
Syed F. A. Hossainy - Fremont CA, US
Assignee:

Abbot Cardiovascular Systems Inc. - Santa Clara CA
International Classification:

A61F 2/02
US Classification:

424423
Abstract:

A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders
view source
US Patent:

8586069, Nov 19, 2013
Filed:

Dec 29, 2005
Appl. No.:

11/322282
Inventors:

Gordon Stewart - San Francisco CA, US
Gina Zhang - Fremont CA, US
Nancy Kirsten - San Carlos CA, US
Paul Consigny - San Jose CA, US
Stephen Dugan - San Francisco CA, US
Gene Park - Oakland CA, US
Christopher Feezor - San Jose CA, US
Wouter Roorda - Palo Alto CA, US
Syed Faiyaz Ahmed Hossainy - Fremont CA, US
Assignee:

Abbott Cardiovascular Systems Inc. - Santa Clara CA
International Classification:

A61F 13/00
A61F 2/00
US Classification:

424422, 424423
Abstract:

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders
view source
US Patent:

20060002968, Jan 5, 2006
Filed:

Jun 30, 2004
Appl. No.:

10/882506
Inventors:

Gordon Stewart - San Francisco CA, US
Gina Zhang - Fremont CA, US
Nancy Kristen - San Carlos CA, US
Paul Consigny - San Jose CA, US
Stephen Dugan - San Francisco CA, US
Gene Park - Oakland CA, US
Christopher Feezor - San Jose CA, US
Wouter Roorda - Palo Alto CA, US
Syed Hossainy - Fremont CA, US
International Classification:

A61K 31/4745
A61F 2/00
US Classification:

424423000, 514291000
Abstract:

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

Stents With Radiopaque Markers
view source
US Patent:

20070156230, Jul 5, 2007
Filed:

Jan 4, 2006
Appl. No.:

11/325973
Inventors:

Stephen Dugan - San Francisco CA, US
Anthony Abbate - Santa Clara CA, US
International Classification:

A61F 2/90
US Classification:

623001160, 623001340
Abstract:

Various embodiments of stents with radiopaque markers disposed within depots in the stent, are described herein.

Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders With An Implantable Medical Device
view source
US Patent:

20100322992, Dec 23, 2010
Filed:

Jul 16, 2010
Appl. No.:

12/838329
Inventors:

Stephen Dugan - San Francisco CA, US
International Classification:

A61F 2/82
A61K 31/573
A61P 9/08
A61P 35/00
A61P 29/00
US Classification:

424423, 514171, 623 115, 623 142
Abstract:

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque

Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders With An Implantable Medical Device
view source
US Patent:

7758881, Jul 20, 2010
Filed:

Mar 24, 2005
Appl. No.:

11/090507
Inventors:

Stephen Dugan - San Francisco CA, US
Assignee:

Advanced Cardiovascular Systems, Inc. - Santa Clara CA
International Classification:

A61F 2/02
US Classification:

424423
Abstract:

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-inflammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

Systems, Devices, And Methods For Tracking Abdominal Orientation And Activity For Treatment And Prevention Of Pressure Sores
view source
US Patent:

20230113555, Apr 13, 2023
Filed:

Dec 2, 2022
Appl. No.:

18/074368
Inventors:

- San Francisco CA, US
Stephen Dugan - San Francisco CA, US
International Classification:

A61B 5/00
A61B 5/11
A61B 5/107
A61B 5/06
G16H 40/63
G16H 50/30
A61B 5/053
Abstract:

Methods and devices for monitoring and changing the physical orientation of an individual are provided. A method includes providing a wearable device that monitors the physical orientation of an individual, monitoring the physical orientation over time using the wearable device, and issuing an alert from the wearable device to change the physical orientation by a prescribed amount when the individual has maintained the physical orientation for a duration exceeding a maximum length. The wearable device is optionally configured to issue subsequent alerts upon determining that the physical orientation has not changed following the duration. The alerts are optionally of varying natures and issued to, for example, the individual, people nearby, and/or caregivers outside the individual's room.

Systems, Devices, And Methods For Tracking Abdominal Orientation And Activity For Prevention Of Poor Respiratory Disease Outcomes
view source
US Patent:

20210077010, Mar 18, 2021
Filed:

Dec 1, 2020
Appl. No.:

17/109068
Inventors:

- San Francisco CA, US
Stephen Dugan - San Francisco CA, US
International Classification:

A61B 5/00
A61B 5/11
A61B 5/107
A61B 5/06
G16H 40/63
G16H 50/30
A61B 5/053
Abstract:

The disclosed apparatus, systems and methods relate to tracking abdominal orientation and activity for purposes of preventing or treating conditions of pregnancy, respiratory diseases or other types of medical conditions. In certain specific embodiments, the system, device, or method relates to identifying abdominal or sleep position orientation risk values, calculating and updating a cumulative risk value, comparing the cumulative risk value to a threshold, and outputting a warning when the cumulative risk value crosses the threshold.